TABLE 4.
Disclosure of financial interactions in clinical trials
| Percentage of respondents that desire disclosure of financial interactions | ||||
|---|---|---|---|---|
| Yes (%) | Yes, if above certain monetary value (%) | No (%) | Unsure (%) | |
| Gifts overall | 318, 965 | 268 | 18 | 18 |
| Salary support | 813 | — | — | — |
| Stock ownership | 783 | — | — | — |
| Per-patient payment | 863 | — | — | — |
| Percentage of respondents that find disclosing financial interactions important | |||
|---|---|---|---|
| Extremely important (%)† | Somewhat important (%)† | Little/not very important (%)† | |
| Personal income | 58, 69, 567 | 24, 19, 267 | 17, 12, 187 |
| Researcher patent | 59, 64, 597 | 21, 21, 217 | 20, 15, 207 |
| Researcher stocks | 66, 72, 657 | 17, 15, 197 | 17, 13, 177 |
| Per capita payment | 50, 61, 467 | 27, 23, 267 | 23, 16, 287 |
| Percentage of respondents that require disclosure of financial interactions for informed consent | ||
|---|---|---|
| Yes (%)† | No (%)† | |
| Personal income | 68, 74, 647 | — |
| Researcher patent | 76, 82, 757 | — |
| Researcher stocks | 80, 85, 787 | — |
| Per capita payment | 70, 78, 647 | — |
1
Blake and Early, 1995 (self-administered survey, n=486);
2
Mainous et al. 1995 (telephone survey, n=649);
3
LaPuma et al. 1995 (self-administered survey, n=200);
4
Gibbons et al. 1998 (face-to-face survey, n=196);
5
Eaton 2003 (online poll, n=1,479);
6
Wall Street Journal Online 2003 (online poll, n=4,173);
7
Kim et al. 2004 (Internet-administered survey, n=5,478);
8
Hampson et al. 2006 (face-to-face survey, n=253);
9
Semin et al. 2006 (face-to-face survey, n=253);
10
Weinfurt et al. 2006 (focus group, n=139)
†
Results reported as coronary artery disease group (n=2,355), breast cancer group (n=1,006), depression group (n=2,117), respectively